Fog Pharmaceuticals
PrivateLast Round
Private Placement
Jun 12, 2026
Est. Valuation
$2.3B
Total Funding Raised
$812M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Parabilis Medicines is a biopharmaceutical company that develops Helicon™ peptide therapeutics designed to target and neutralize historically undruggable intracellular cancer-causing proteins.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Fog Pharmaceuticals Comparables
Compare Fog Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Relay Therapeutics | 78% | |
| PeptiDream Inc. | 76% | |
| Recursion Pharmaceuticals | 76% |
Fog Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Private Placement | Jun 12, 2026 | ||||
| IPO | Jun 10, 2026 | ||||
| Series F | Jan 8, 2026 | ||||
| Series E | Mar 1, 2024 | ||||
| Series D | Nov 21, 2022 | ||||
Series C | Mar 1, 2021 |
Fog Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series F |
| Deerfield Management | Series C, Series A, Seed, Series B, Series D |
| Evercore ISI | IPO |
| Janus Henderson Group | Series F |
| Horizons Ventures | Series B |
| SymBiosis Capital Management | Series E |
| Boyu Capital | Seed, Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 12, 2026
$75M round with participation from Regeneron Pharmaceuticals.
- Jun 10, 2026
$771M IPO round led by Guggenheim Securities.
Fog Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Fog Pharmaceuticals's valuation, stock price, and market status.
Is Fog Pharmaceuticals a public or private company?
Fog Pharmaceuticals is a private company.
What is the current stock price of Fog Pharmaceuticals?
Fog Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Fog Pharmaceuticals worth (valuation)?
Valuation information for Fog Pharmaceuticals is not publicly available.
Can I buy Fog Pharmaceuticals stock?
Fog Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Fog Pharmaceuticals's last funding round?
Fog Pharmaceuticals's most recent funding round was Series E on March 1, 2024.
Who are the main investors in Fog Pharmaceuticals?
Key investors in Fog Pharmaceuticals include Deerfield Management, Farallon Capital Management, GV, Fidelity Management & Research Company, ARCH Venture Partners.
Will Fog Pharmaceuticals IPO soon?
No public IPO plans have been announced for Fog Pharmaceuticals.
How can I track Fog Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Fog Pharmaceuticals's secondary market activity and sign up for updates.